Disease dynamics
|
Proportion of infections due to the Omicron variant () |
50%, 95% |
Assumption with sensitivity analysis |
Mean latent time |
3.5 days |
Average of Delta (4 days) and Omicron (3 days), based on CDC55, |
Mean time to recovery |
5 days |
CDC56
|
Disease transmission
|
Ratio of basic reproduction numbers Omicron:Delta |
3:1 |
Ito et al.49, Scientific American50, and based on Liu and Rocklöv51
|
Inputs for basic reproduction number of (variant, group) in the best-, base-, worst-case scenarios, respectively: |
Delta, students |
5, 6, 7 |
Assumption with sensitivity analysis, based on57
|
Omicron, students |
|
Assumption with sensitivity analysis |
Delta, faculty |
2.2, 3.2, 4.2 |
Assumption with sensitivity analysis, based on57
|
Omicron, faculty |
|
Assumption with sensitivity analysis |
Reduction in disease transmission rate under a face mask policy () |
50% |
Zhang et al.58
|
Disease outcomes
|
Vaccine effectiveness against infection for (variant, vaccination status) |
Delta, vaccinated |
80% |
Bruxvoort et al.59
|
Omicron, vaccinated |
33% |
BMJ60
|
Delta, boosted |
86.7% |
Bruxvoort et al.59
|
Omicron, boosted |
69.4% |
Paul61
|
Symptom development rate for infected (all vaccination status) |
30% |
Assumption (similar to Paltiel et al.12), also based on Poletti et al.62
|
Hospitalization rate for symptomatic and unvaccinated (students/faculty) |
1.4%/8.4% |
CDC63, COVID-Net64, Rabil et al.30
|
Vaccine effectiveness against hospitalization for symptomatic (variant, vaccination status) |
Omicron, vaccinated |
70% |
BMJ60
|
Delta, vaccinated |
91.7% |
Andrews et al.65
|
Omicron, boosted |
93% |
Based on Thompson et al.8
|
Delta, boosted |
97.5% |
Bruxvoort et al.59
|
Fatality rate for hospitalized and unvaccinated (students/faculty) |
0.05%/2% |
Rabil et al.30, Statista66,67
|
Screening test characteristics
|
Test sensitivity (sens) |
80% |
Based on Stites andWilen68, Woloshin et al.69, Yohe70
|
Test specificity (spec) |
98% |
Yohe70
|
Coverage characteristics at the start of the semester
|
Proportion of vaccinated |
82% |
Based on Nietzel71, Mauer72, and Mayo Clinic73
|
Proportion of boosted |
38% |
Based on Anderson74 and CDC75
|
|
64% |
Based on Virginia Tech76 and CDC75
|